Related references
Note: Only part of the references are listed.Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation A Systematic Review
Jodi B. Segal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Smoking and venous thromboembolism: a Danish follow-up study
M. T. Severinsen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
Hagen Kennecke et al.
CANCER (2008)
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations
Elisabeth R. Pomp et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
Trevor J. Powles et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of Factor v Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
Neil Abramson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter
M Mandalà et al.
ANNALS OF ONCOLOGY (2004)
Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer
AK Fink et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology
M Cushman et al.
AMERICAN JOURNAL OF MEDICINE (2004)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer
C Duggan et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
AH Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Overview of the main outcomes in breast-cancer prevention trials
J Cuzick et al.
LANCET (2003)
Tamoxifen and depression: More evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) randomized study
R Day et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
